VHL disease and HIF-2alpha inhibitor

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center in Houston, Texas, USA speaks about the use of  hypoxia-inducible factor (HIF) 2alpha inhibitor for the treatment of renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease. Firstly, Dr Jonasch describes how HIF-2alpha combines with HIF-1beta to act as a transcription factor […]

read more

ESMO 2019: First in human study of HIF-2α inhibitor in patients with advanced kidney cancer

Results from the first in human study of the HIF-2α inhibitor, PT2977 in patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Hypoxia inducible factor 2α (HIF-2α) is known to stimulate the growth of tumours via the von Hippel-Lindau (VLH) group of genes. PT2977 […]

read more

HIF-2α inhibitor shows promise in patients with advanced kidney cancer

A recent phase I/II clinical trial with PT2977, a hypoxia-inducible factor (HIF)-2α inhibitor, has shown encouraging anti-tumour activity with a favourable safety profile in patients with previously-treated advanced renal cell carcinoma (RCC). Of the 55 patients who were treated with the HIF-2α inhibitor, 12 patients (22%) had a confirmed partial response. The study is still […]

read more

A new class of anti-cancer drug for kidney cancer shows promise

Researchers in America are looking at a new class of anti-cancer drug, called hypoxia inducible factor-2a (HIF-2a) inhibitors. In a study published in the Journal of Clinical Oncology initial findings with a novel drug belonging to the HIF-2a class of medicines show promise in treating metastatic kidney cancer. In the study, 51 patients with aggressive kidney cancer that had received an average […]

read more

HIF-2α inhibitor shows promise in renal cell carcinoma

The results of a first-in-human phase I clinical trial with a new drug called PT2385 were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago last week. PT2385 is an inhibitor of hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other […]

read more
Showing 11 to 15 of 15 results